These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. Montefiori DC; Robinson WE; Mitchell WM AIDS Res Hum Retroviruses; 1989 Apr; 5(2):193-203. PubMed ID: 2469450 [TBL] [Abstract][Full Text] [Related]
23. 1984-Discovery of the First Anti-HIV Drug, Suramin. De Clercq E Viruses; 2021 Aug; 13(8):. PubMed ID: 34452510 [TBL] [Abstract][Full Text] [Related]
24. [Chemotherapeutic possibilities in HIV infection]. Vogt MW; Lüthy R; Siegenthaler W Verh Dtsch Ges Inn Med; 1988; 94():531-6. PubMed ID: 3061229 [No Abstract] [Full Text] [Related]
25. Progress in the development of antiviral therapy for HTLV-III-associated diseases. Yarchoan R; Broder S Important Adv Oncol; 1987; ():293-311. PubMed ID: 2841232 [No Abstract] [Full Text] [Related]
27. [Attempts at the treatment of acquired immunodeficiency syndrome (AIDS)]. Turek-Urasińska K Pol Tyg Lek; 1987 Dec; 42(49):1551-3. PubMed ID: 3330216 [No Abstract] [Full Text] [Related]
28. The effect of alcohol on HIV infection in vitro. Saravolatz LD; Cerra RF; Pohlod DJ; Smereck S Prog Clin Biol Res; 1990; 325():267-71. PubMed ID: 2105508 [No Abstract] [Full Text] [Related]
29. [Can HIV/AIDS be healed with new therapies?]. Battegay M Praxis (Bern 1994); 1997 May; 86(22):931-2. PubMed ID: 9289789 [No Abstract] [Full Text] [Related]
30. Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. Eeftinck Schattenkerk JK; Danner SA; Lange JM; Paul DA; van Boxtel CJ; Miedema F; Schellekens PT; Goudsmit J Arch Intern Med; 1988 Jan; 148(1):209-11. PubMed ID: 2447847 [TBL] [Abstract][Full Text] [Related]
31. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. Gartner S; Markovits P; Markovitz DM; Betts RF; Popovic M JAMA; 1986 Nov; 256(17):2365-71. PubMed ID: 3490587 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of infectivity of HTLV-III in vitro. Mitsuya H; Matsushita S; Harper ME; Broder S Cancer Res; 1985 Sep; 45(9 Suppl):4583s-4587s. PubMed ID: 2990689 [TBL] [Abstract][Full Text] [Related]
33. Isolation of HTLV III/LAV from drug addicts in Palermo. Romano N; Portera M; Vitale F; Russo Alesi D; Torregrossa MV; Perrera G Microbiologica; 1987 Jan; 10(1):73-80. PubMed ID: 3646455 [TBL] [Abstract][Full Text] [Related]
34. [AIDS: when a nightmare becomes controllable...]. Fortschr Med; 1998 Jan; 116(3):10-1. PubMed ID: 9522539 [No Abstract] [Full Text] [Related]
35. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487 [TBL] [Abstract][Full Text] [Related]
36. Combination therapy for chronic hepatitis B. Fontana RJ; Lok AS Hepatology; 1997 Jul; 26(1):234-7. PubMed ID: 9214476 [No Abstract] [Full Text] [Related]
37. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168 [TBL] [Abstract][Full Text] [Related]